000 01256 a2200337 4500
005 20250515092505.0
264 0 _c20071113
008 200711s 0 0 eng d
022 _a1744-7682
024 7 _a10.1517/14712598.7.11.1615
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGeskey, Joseph M
245 0 0 _aPalivizumab in congenital heart disease: should international guidelines be revised?
_h[electronic resource]
260 _bExpert opinion on biological therapy
_cNov 2007
300 _a1615-20 p.
_bdigital
500 _aPublication Type: Editorial
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aAntiviral Agents
_xtherapeutic use
650 0 4 _aChild
650 0 4 _aHeart Defects, Congenital
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aInternational Cooperation
650 0 4 _aPalivizumab
650 0 4 _aPractice Guidelines as Topic
650 0 4 _aRespiratory Syncytial Virus Infections
_xdrug therapy
700 1 _aThomas, Neal J
700 1 _aBrummel, Gretchen L
773 0 _tExpert opinion on biological therapy
_gvol. 7
_gno. 11
_gp. 1615-20
856 4 0 _uhttps://doi.org/10.1517/14712598.7.11.1615
_zAvailable from publisher's website
999 _c17480424
_d17480424